DOCSLIB.ORG

The Role of Biologics Agent in the Treatment of In.Ammatory Bowel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

REVIEW ARTICLE 7KH5ROHRI%LRORJLFV$JHQWLQWKH7UHDWPHQW RI,QÀDPPDWRU\%RZHO'LVHDVH Tri Hapsoro Guno*, Marcellus Simadibrata** *Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta **Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta Corresponding author: Marcellus Simadibrata. Division of Gastroenterology, Department of Internal Medicine, Dr. Cipto Mangunkusumo *HQHUDO1DWLRQDO+RVSLWDO-O'LSRQHJRUR1R-DNDUWD,QGRQHVLD3KRQH)DFVLPLOH (PDLOSURIPDUFHOOXVV#JPDLOFRP ABSTRACT ,QÀDPPDWRU\ERZHOGLVHDVH ,%' ZLWKPDMRUPDQLIHVWDWLRQVDV&URKQ¶VGLVHDVH &' DQGXOFHUDWLYHFROLWLV 8& LVDFKURQLFLQWHVWLQDOLQÀDPPDWRU\GLVRUGHUZLWKDQXQNQRZQHWLRORJ\ZKLFKSDWKRJHQVLVLQYROYLQJ PXOWLIDFWRULDOLPPXQHGLVRUGHUFKDUDFWHUL]HGE\FKURQLFUHODSVLQJLQÀDPPDWLRQRIWKHLQWHVWLQH0DQDJHPHQW RI,%'GHSHQGVRQVWDJHDQGORFDWLRQRIWKHLQÀDPPDWLRQFRQVLVWRIWKHFODVVLFFRQYHQWLRQDOWUHDWPHQWDQG the more new treatment with biologics agent. Biologics agent refers to monoclonal antibodies with activity GLUHFWHGDJDLQVWVSHFL¿FWDUJHWVLQYROYHGLQWKHSDWKRJHQHVLVRIFKURQLFLQÀDPPDWRU\FRQGLWLRQV$GYDQFHVLQ WKHXQGHUVWDQGLQJRIWKHVSHFL¿FPHFKDQLVPVRISDWKRJHQHVLV,%'OHGWRWKHGHYHORSPHQWRIWDUJHWHGWUHDWPHQW Today there are six biologics agent approved and used as therapy and there still many other biologics agent on UHVHDUFKSURJUHVV0DQ\UHSRUWVVKRZSRVLWLYHUHSRUWDERXWHI¿FDF\IRUWKHELRORJLFDOWKHUDS\FRPSDUHGZLWK placebo and conventional treatment for the IBD. Limited by their cost and adverse effect that possibly happened, biologics agent is still promising therapy that change the course of IBD treatment. Keywords:,QÀDPPDWRU\ERZHOGLVHDVH ,%' &URKQ¶VGLVHDVH &' XOFHUDWLYHFROLWLV 8& ELRORJLFDO therapy, biologics agent. ABSTRAK 3HQ\DNLWLQÀDPPDWRU\ERZHOGLVHDVH ,%' WHUEDJLPHQMDGLSHQ\DNLW&URKQGDQNROLWLVXOVHUDWLIPHUXSDNDQ SHUDGDQJDQNURQLVLQÀDPDWRULNGHQJDQHWLRORJL\DQJEHOXPMHODVGLNHWDKXLGDQPHOLEDWNDQJDQJJXDQ LPXQLWDVPXOWLIDNWRULDOGLNDUDNWHULVWLNDQGHQJDQLQÀDPDVLXVXV\DQJEHUXODQJVHFDUDNURQLV7DWDODNVDQD dari IBD bergantung kepada derajat penyakit dan lokasi lesi, tatalaksana terdiri dari terapi konvensional dan WHUDSLWHUEDUXGHQJDQDJHQELRORJLV$JHQELRORJLVPHUXSDNDQDQWLERGLPRQRNORQDO\DQJPHPLOLNLDNWL¿WDV PHQJKDPEDWWDUJHWVSHVL¿NGDODPSURVHVLQÀDPDVLSDGD,%''HQJDQVHPDNLQEHUNHPEDQJQ\DSHPDKDPDQ tentang mekanisme dari patogenesis IBD saat ini memicu perkembangan berbagai jenis agen biologis. Saat ini ada enam jenis agen biologis yang sudah disetujui dan digunakan sebagai terapi IBD dan banyak agen ELRORJLVODLQVHGDQJGDODPWDKDSSHQHOLWLDQ%HUEDJDLSHQHOLWLDQPHQXQMXNDQHIHNWL¿WDVWHUDSLELRORJLVDSDELOD dibandingkan dengan plasebo dan terapi konvensional. Walaupun penggunaanya masih terbatas dikarenakan masalah biaya dan efek samping yang mungkin terjadi, agen biologis tetap merupakan terapi yang menjanjikan dan dapat merubah tatalaksana IBD. Kata kunci: LQÀDPPDWRU\ERZHOGLVHDVH ,%' SHQ\DNLW&URKQNROLWLVXOVHUDWLIWHUDSLELRORJLVDJHQELRORJLV 184 The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease INTRODUCTION (3,'(0,2/2*< $1' 5,6. )$&725 2) ,1)/$00$725<%2:(/',6($6( +HDOWKFDUHEXUGHQIRUPDQDJHPHQWRILQÀDPPDWRU\ bowel disease (IBD) is substantially high but has been IBD can be diagnosed at any age from infancy to evolved since the introduction of biologics agent in geriatrics population, with the majority of new cases WKHEHJLQQLQJRIWKHWZHQW\¿UVWFHQWXU\VLQFHLWV are diagnosed in adolescence and early adulthood. impact on reducing the need of surgeries and improved In early twentieth century the incidence of IBD rose quality of life for IBD patient.1 Pathogensis on IBD steadily in the western world but relatively rare in involving multifactorial immune disorder characterized developing nations, but over the past few decades IBD E\FKURQLFUHODSVLQJLQÀDPPDWLRQRIWKHLQWHVWLQH also found emerged in newly industrialized countries The two major manifestations of IBD were Crohn’s such as in Asia, South America and Middle East and disease (CD) and ulcerative colitis (UC) which share has evolved into a global disease with rising prevalence similar symptoms including diarrhea, hematochezia, in every continent.5,6 and abdominal pain, whereas the location and depth of Over 1 million residents in the USA and 2.5 LQÀDPPDWLRQDVZHOODVFRPSOLFDWLRQVDQGSUHYDOHQFH million in Europe are estimated to have IBD, with can differ.2,3 substantial costs for health care. From ACCESS Normally the immune system in gastrointestinal study, crude annual incidence of IBD per 100,000 tract make a complex interaction between the innate, individuals were 1.37 in Asia. Incidence of IBD adaptive immune systems and intestinal microbes under case in Indonesia was 0.88 per 100,000 individuals, homeostatic conditions. This homeostasis is disrupted with CD incidence was 0.33 and UC incidence was ZLWKUHVXOWRIXQFRQWUROOHGLQWHVWLQDOLQÀDPPDWLRQ 0.55.7 Epidemiological differences in IBD between in IBD. Therapy with most non-biological drug the western world and newly industrial ized countries (aminosalicylates, steroids and immuno-modulators) are primarily explained by genetic and environmental provide symptomatic improvement but fail to stop the LQÀXHQFHVRQGLVHDVHGHYHORSPHQW Advances in health- XQGHUO\LQJLQÀDPPDWRU\SURFHVVDQGGRQRWFKDQJHWKH care infrastructure and methodological challenges disease course. Biologics therapy for IBD have been in reporting epidemiological data also influence revolutionized the treatment of patients with Crohn’s differences in reported incidence between countries disease and have begun to have an impact on therapy and world regions. 7KH¿JXUHEHORZVXPPDUL]HWKH for refractory ulcerative colitis. Biologics therapy KLVWRULFDORI,%'IURPWKH¿UVWLQWURGXFH1 proven to be highly effective.2-4 )LJXUH7KHJOREDOSUHYDOHQFHRI,%'LQ Volume 18, Number 3, December 2017 185 Tri Hapsoro Guno, Marcellus Simadibrata )LJXUH+LVWRULFDOWLPHOLQHVRILQÀPPDWRU\ERZHOGLVHDVH ,%' WKURXJKRXWWKHZRUOG1 ,%'LVDFKURQLFLQWHVWLQDOLQÀDPPDWRU\GLVRUGHU breast-feeding prove the role of the intestinal with an unknown etiology. IBD has been thought to be PLFURELRWDLQPRGXODWLQJLQÀDPDWLRQ'LHWDU\IDFWRUV LGLRSDWKLFEXWLQÀXHQFHGE\JHQHWLFDQGHQYLURQPHQWDO VXFKDVDORZ¿EUHGLHWDQGKLJKGLHWDU\IDWLQGLHWV factors.2 It is believed to manifest in genetically are associated with IBD, whereas consumption of tea predisposed individuals who has an abnormal immune was protective for IBD in Asia.1 response toward intestinal microbes after exposure to environmen tal triggers. Untill now 163 loci are 3$7+2*(1(6,6$1',0081(0(&+$1,606,1 known to confer susceptibility to Crohn’s disease ,1)/$00$725<%2:(/',6($6( ,%' and/or ulcerative colitis. Genes with the strongest Human intestine service as a immune system with associations are involved in the immune response to complex interaction occured. Idiopathic intestinal microbes, such as innate sensing of bacteria (NOD2), LQÀDPPDWLRQVVXFKDV,%'RFFXUZKHQEDODQFHRIWKLV WKHLQÀDPPDWRU\UHVSRQVHWRPLFUREHV ,/5 DQG immune system disrupted. Initially T-helper-1 (Th1) autophagy (ATG16L1).1 cells have been thought to play an important role in Environmental exposures contribute to the etiology pathogenesis related to the chronicity of intestinal of IBD. Many of them have been studied, but none LQÀDPPDWLRQHVSHFLDOO\LQ&'ZKHUHDV7KFHOOV funda mentally can explain the truth pathogenesis have been thought to play an important role mainly of IBD. In the western world, smoking is the most in UC. Recently, additional factor like activation of consistently studied environmental determinant of Th17 cells and imbalance of Th17/T regulatory (Treg) IBD. The hygiene hypothesis postulates that children in cells are recognized to be an important component of industrialized and high urbanization society have less IBD pathogenesis. Some other cells show to involved exposure to microbes early in life, such that infections in the pathogenesis of IBD as can be viewed in this later will trigger an abnormal host immune response. Figure below.2,3 Risk of IBD associated with antibiotic use in childhood, )LJXUH3URLQÀDPPDWRU\LPPXQHFHOOVDQGWKHLUFURVVWDONLQSDWLHQWVZLWK,%'3 T reg FHOO UHJXODWRU\ 7 FHOO 7*) WUDQVIRUPLQJ JURZWK IDFWRU 7H W\SH 7 KHOSHU FHOO 7H2: type 2 7 KHOSHU FHOO7H W\SH 7 KHOSHU FHOO7H W\SH 7 KHOSHU FHOO 1. FHOO QDWXUDO NLOOHU FHOO ,/ LQWHUOHXNLQ ,)1LQWHUIHURQ71)WXPRUQHFURVLVIDFWRU 186 The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease (SLWKHOLDODQG&RPPHQVDO%DFWHULD ,QQDWH DQG$GDSWLYH ,PPXQLW\ LQ ,QÀDPPDWRU\ Epithelial surface of intestine acts as a barrier %RZHO'LVHDVH ,%' from harmful pathogens and place where commensal The innate immune system serve as first line microorganisms live. The imbalance interaction defensive against external pathogens. It provides between imune system with microbes develop chronic rapid and non-specific protection from pattern LQWHVWLQDOLQÀDPPDWLRQZKHQFHUWDLQHQYLURQPHQWDO recognition of pathogens. Human intestine innate factors triggers the genetically susceptible hosts. The immune system is composed of intestine epithelia, intestinal epithelial cell (IEC) layer make crypts and macrophages, monocytes, neutrophils, eosinophils, villi of intestine which contain different cells including basophils, dendritic cells (DCs), and natural killer enterocytes, goblet cells, neuroendocrine cells, Paneth cells. Intraluminal pathogens communicate with innate cells, M cells, and
Recommended publications
  • Recent Advances in Inflammatory Bowel Disease: Mucosal Immune

    Recent Advances in Inflammatory Bowel Disease: Mucosal Immune

    Recent advances in basic science Recent advances in inflammatory bowel disease: Gut: first published as 10.1136/gutjnl-2012-303955 on 8 October 2013. Downloaded from mucosal immune cells in intestinal inflammation M Zaeem Cader,1,2 Arthur Kaser1 1Department of Medicine, ABSTRACT Recent years have seen a rapid and exciting Division of Gastroenterology & The intestine and its immune system have evolved to expansion in our understanding of the mucosal Hepatology, University of Cambridge, Addenbrooke’s meet the extraordinary task of maintaining tolerance to immune system with novel insights into environ- Hospital, Cambridge, UK the largest, most complex and diverse microbial mental influences of diet and the microbiota; the 2Wellcome Trust PhD commensal habitat, while meticulously attacking and convergence and integration of fundamental cellu- Programme for Clinicians, containing even minute numbers of occasionally lar processes such as autophagy, microbial sensing Cambridge Institute for incoming pathogens. While our understanding is still far and endoplasmic reticulum (ER) stress; as well as Medical Research, School of Clinical Medicine, University of from complete, recent studies have provided exciting the discovery of new cell types, for example innate Cambridge, Cambridge, UK novel insights into the complex interplay of the many lymphoid cells (ILCs). distinct intestinal immune cell types as well as the The gut is unlike the systemic immune system in Correspondence to discovery of entirely new cell subsets. These studies have several respects and much of the extensive reper- Dr Arthur Kaser, Department of Medicine, Division of also revealed how proper development and function of toire of immune cells and their characteristics are Gastroenterology and the intestinal immune system is dependent on its specific indeed unique to the intestine.
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • HY 2021 Results

    HY 2021 Results

    Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
  • Immunfarmakológia Immunfarmakológia

    Immunfarmakológia Immunfarmakológia

    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
  • Novel Therapies for Eosinophilic Disorders

    Novel Therapies for Eosinophilic Disorders

    Novel Therapies for Eosinophilic Disorders Bruce S. Bochner, MD KEYWORDS Eosinophil Therapies Antibodies Targets Pharmacology Biomarkers KEY POINTS A sizable unmet need exists for new, safe, selective, and effective treatments for eosinophil-associated diseases, such as hypereosinophilic syndrome, eosinophilic gastrointestinal disorders, nasal polyposis, and severe asthma. An improved panel of biomarkers to help guide diagnosis, treatment, and assessment of disease activity is also needed. An impressive array of novel therapeutic agents, including small molecules and biologics, that directly or indirectly target eosinophils and eosinophilic inflammation are undergoing controlled clinical trials, with many already showing promising results. A large list of additional eosinophil-related potential therapeutic targets remains to be pursued, including cell surface structures, soluble proteins that influence eosinophil biology, and eosinophil-derived mediators that have the potential to contribute adversely to disease pathophysiology. INTRODUCTION Eosinophilic disorders, also referred to as eosinophil-associated diseases, consist of a range of infrequent conditions affecting virtually any body compartment and organ.1 The most commonly affected areas include the bone marrow, blood, mucosal sur- faces, and skin, often with immense disease- and treatment-related morbidity, Disclosure Statement: Dr Bochner’s research efforts are supported by grants AI072265, AI097073 and HL107151 from the National Institutes of Health. He has current or recent consul- ting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-A- ventis, Pfizer, Svelte Medical Systems, Biogen Idec, TEVA, and Allakos, Inc. and owns stock in Allakos, Inc. and Glycomimetics, Inc. He receives publication-related royalty payments from Elsevier and UpToDate and is a coinventor on existing and pending Siglec-8-related patents and, thus, may be entitled to a share of future royalties received by Johns Hopkins University on the potential sales of such products.
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T

    WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
  • Roche Investor Presentation Oppenheimer 23Rd Annual

    Roche Investor Presentation Oppenheimer 23Rd Annual

    Roche: Oppenheimer 23rd Annual Healthcare Conference Thomas Kudsk Larsen, Head of Investor Relations North America, New York, 12 December 2012 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1. pricing and product initiatives of competitors; 2. legislative and regulatory developments and economic conditions; 3. delay or inability in obtaining regulatory approvals or bringing products to market; 4. fluctuations in currency exchange rates and general financial market conditions; 5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6. increased government pricing pressures; 7. interruptions in production; 8. loss of or inability to obtain adequate protection for intellectual property rights; 9. Litigation; 10. loss of key executives or other employees; and 11. adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website2 www.roche.com.
  • Minutes PDCO 25-28 February 2020

    Minutes PDCO 25-28 February 2020

    26 February 2020 EMA/PDCO/104692/2020 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO) Minutes for the meeting on 25-28 February 2020 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.